Hikma Pharmaceuticals PLC (HIK) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, all, and thank you for joining us for the HICMA Interim Results Call. My name is Carly, and I'll be coordinating the call today. During the presentation, you can register a question by pressing star followed by one on your telephone keypad, and to remove yourself from that line of questioning, please press star followed by two. I'll now hand over to Riyad Mishlawi, CEO, to begin. Okay, good morning, everyone. It's always great to sit in front of you, and we have good results today. It makes today much more pleasing. Anyways, I just wanted to go over some maybe overall messages. We had, as you all know, we had an excellent performance in H1. Revenue has increased by about 10% with the three businesses performing well, underpinned by our strong commercial and operational capabilities. We continue to invest in the businesses. and deliver on our corporate strategy. In the first half, we had grown our portfolio, launching 59 products across our businesses and continued to strengthen our pipeline with more than 300 products currently in the pipeline. We further strengthened our leadership team. As you know, we had some additions. We had some shuffling around and some changes in responsibilities. We announced the strategic acquisitions of Zellium products. The Zellium acquisition included products, manufacturing facility, and R&D assets. Of course, as you know, we're still waiting for the final FTC approvals. We expanded into other territories, especially in Europe, in both UK, Spain, doing exceptionally well there. We're well positioned for sustainable long-term growth and have upgraded our guidance for this year. Group revenue expected to grow in the range of 6% to 8%, up from 4% to 6%, Group core operating profits to be in the range of $700 million to $730 ...